Press

PsyBio Therapeutics Reports Second Quarter 2022 Financial Results

Aug 29 • 3 min read

PsyBio Therapeutics Corp. (TSXV: PSYB | OTCQB: PSYBF), a fully integrated and intellectual property driven biotechnology company developing novel psychoactive medicinal candidates targeting the potential treatment of mental health challenges, neurological disorders and other human health conditions, today announced that it has reported its unaudited interim financial results for the three and six month period ended June 30,…

B.More Receives FDA Investigational New Drug Approval for Psilocybin Alcohol Use Disorder Program Phase 2b Clinical Trial

Aug 26 • 2 min read

B.More Inc., a 501(c)(3) non-profit, clinical-stage biopharmaceutical company focused on the development of psychedelic medicines for substance abuse disorders, today announced that the U.S. Food and Drug Administration has approved its IND application to begin a Phase 2b clinical trial to determine the efficacy and safety of synthetic psilocybin (SYNP-101) in treating patients with alcohol use disorder…

Filament Health Appoints New Members To Board Of Directors And Advisory Council

Aug 26 • 3 min read

Filament Health Corp. (OTCQB: FLHLF | NEO: FH | FSE: 7QS), a clinical‐stage natural psychedelic drug development company, today announced the appointment of Dr. Konstantin Adamsky of Negev Capital to its Board of Directors, and Jeff Chilton of Nammex to the Company’s Advisory Council. Konstantin Adamsky, PhD, is the Chief Operating Officer of Negev Capital, a psychedelic medical intervention investment fund that has made…

PharmaDrug Advances Psychedelics Pharmaceutical Program Focused on DMT and DMT Analogues

Aug 26 • 7 min read

PharmaDrug Inc. (CSE: PHRX | OTCQB: LMLLF), a specialty pharmaceutical company focused on the research, development and commercialization of psychedelics and other naturally-derived approved drugs, is pleased to announce that the Company continues to successfully execute on key objectives related to its multiprong psychedelics research and development strategy by generating potential shareholder value through a…

Awakn Life Sciences Signs Agreement with a Leading Drug Development Company to Deepen IP Moat for Its Lead Program

Aug 26 • 3 min read

Awakn Life Sciences Corp. (NEO: AWKN | OTCQB: AWKNF | FSE: 954), a revenue-generating biotechnology company researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announced today it has signed a twelve month option agreement with a leading drug development, manufacturing, and delivery systems company to in-license…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436